Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

756
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
756
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

345
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
345
Hepatitis01:25

Hepatitis

37
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Hepatic Portal System01:21

Hepatic Portal System

7.8K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk-based pathology reporting after endoscopic submucosal dissection for early gastrointestinal cancer: international consensus standards.

Gut·2026
Same author

Detection of high-grade dysplasia and adenocarcinoma in Barrett's esophagus using high-resolution virtual chromoendoscopy versus the Seattle protocol: the CONVERSE study.

BMC gastroenterology·2026
Same author

Safety and efficacy of extended surveillance intervals following colorectal endoscopic submucosal dissection: an international multicentre study.

Gut·2026
Same author

Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.

JHEP reports : innovation in hepatology·2026
Same author

Inter and intra-observer agreement for the LST Classification in Large (>2cm) Colorectal Laterally Spreading Tumours.

The American journal of gastroenterology·2026
Same author

Impact of knife size and saline-optimized electrosurgical modes on tissue effects in saline-immersion third-space endoscopy.

Scientific reports·2026

Related Experiment Video

Updated: Mar 29, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

[Hepatic encephalopathy].

Jérémie Jacques1, Paul Carrier1, Marilyne Debette-Gratien1

  • 1CHU de Limoges, service d'hépato-gastroentérologie, 2, avenue Luther-King, 87042 Limoges, France.

Presse Medicale (Paris, France : 1983)
|November 25, 2015
PubMed
Summary

Hepatic encephalopathy, a severe liver cirrhosis complication, presents treatment challenges. Emerging therapies like non-absorbable antibiotics offer new hope for managing this condition.

More Related Videos

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.4K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

12.0K

Related Experiment Videos

Last Updated: Mar 29, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.4K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

12.0K

Area of Science:

  • Hepatology
  • Neurology
  • Gastroenterology

Context:

  • Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis.
  • It poses significant social and economic burdens.
  • Current understanding of HE pathophysiology, particularly cerebral mechanisms, remains incomplete, despite ammonia's recognized role.

Purpose:

  • To review the current understanding and therapeutic challenges of hepatic encephalopathy.
  • To highlight the limitations of existing treatments.
  • To introduce emerging therapeutic strategies for HE.

Summary:

  • Hepatic encephalopathy (HE) is a severe complication of liver cirrhosis, presenting a significant therapeutic challenge.
  • While ammonia plays a key role, the precise cerebral mechanisms are not fully understood.
  • Established treatments like disaccharides and trigger management have limited efficacy.
  • Non-absorbable antibiotics, notably rifaximin, represent a promising new therapeutic avenue.

Impact:

  • Provides an overview of hepatic encephalopathy management.
  • Highlights the need for improved therapeutic strategies.
  • Emphasizes the potential of novel treatments like rifaximin in clinical practice.